DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciencesInc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.
The abstracts being presented by Precision and our collaborators this year at ASGCT underscore the differentiated capabilities of our proprietary ARCUS genome editing platform and the breadth of our emerging pipeline applying this technology in vivo, commented Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. These presentations demonstrate the specificity and versatility of ARCUS-driven genome editing in a variety of large animal models and provide further preclinical evidence of potentially meaningful and durable therapeutic impact on a range of genetic and infectious diseases. As we continue to validate ARCUS potential in vivo, we are focused on advancing our gene correction pipeline. We look forward to selecting a clinical candidate for our wholly owned PH1 program, expected in 2020, and, in partnership with Gilead, developing a potential cure for chronic hepatitis B infection, for which submission of an IND is currently targeted for 2021.
Precision BioSciences Presentations:
Title:Engineering a Self-Inactivating Adeno-Associated Virus (AAV) Vector for ARCUS Nuclease DeliveryPoster Session: Gene Targeting and Gene Correction, Abstract: 654Presenting Author: Hui Li, Ph.D., Precision BioSciences
Title:A Gene Editing Approach to Eliminate Hepatitis B Virus Using ARCUS MeganucleasesPoster Session: Gene Targeting and Gene Correction, Abstract 1057Presenting Author: Cassie Gorsuch, Ph.D., Precision BioSciences
Partnered Presentations:
Title: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing - Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis PigmentosaOral Presentation: Gene Therapy for the Special Senses, Abstract 2Date/Time: Tuesday, May 12, 2020, 10:30 10:45 a.m. ESTPresenting Author: Maureen Ann McCall, Ph.D., Professor, Department of Ophthalmology and Visual Sciences, University of Louisville
Title: Evaluation of the Long-term Effects of AAV-Meganuclease Genome Editing of PCSK9 in Macaque LiverOral Presentation: Evaluating Genome Editing Activity and Precision, Abstract 518Date/Time: Wednesday, May 13, 2020, 4:00 4:15 p.m. ESTPresenting Author: Lili Wang, Ph.D., Research Director, Discovery Research and Gene Editing, Research Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
All abstracts for the ASGCT 2020 Meeting are available online at ASGCT Annual Meeting Abstracts.
About Precision BioSciences, Inc.Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visitwww.precisionbiosciences.com.
Forward-LookingStatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing of trials and results from clinical and non-clinical studies of our in vivo gene correction program and the safety, efficacy and delivery of our ARCUS genome editing technology. In some cases, you can identify forward-looking statements by terms such as anticipate, believe, could, expect, should, plan, intend, estimate, target, mission, may, will, would, should, could, target, project, predict, contemplate, potential, or the negative thereof and similar words and expressions.
Forward-looking statements are based on managements current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments; our limited operating history; the success of our programs and product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; our or our collaborators ability to identify, develop and commercialize product candidates; our or our collaborators ability to advance product candidates into, and successfully complete, clinical or field trials; our or our collaborators ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the laws and regulatory landscape that will apply to our and our collaborators development of product candidates; our ability to achieve our anticipated operating efficiencies as we commence manufacturing operations at our new facility; delays or difficulties in enrolling patients in clinical trials; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriate of intellectual property rights; if our product candidates do not work as intended or cause undesirable side effects the potential for off-target editing or other adverse events, undesirable side effects or unexpected characteristics associated with any of our product candidates; risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements; our ability to enter into new collaboration arrangements; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; potential manufacturing problems associated with any of our product candidates; pending and potential liability lawsuits and penalties related to our technology, our product candidates; the outbreak of the novel coronavirus disease (COVID-19); our current and future relationships with third parties; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate key scientific and management personnel; effects of natural or manmade disasters, public health emergencies and other natural catastrophic events; insurance expenses and exposure to uninsured liabilities; market and economic conditions; dilution and fluctuations in our stock price; and other important factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by the risk factor contained in our Current Report on Form 8-K filed with the SEC on April 6, 2020, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SECs website atwww.sec.gov.
All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contacts:Nick RiddlePrecision BioSciencesTel. (919) 314-5512IR@precisionbiosciences.com
Josh RappaportStern Investor RelationsTel. (212) 362-1200josh.rappaport@sternir.com
Media Contact:Maurissa MessierPrecision BioSciencesTel. (919) 314-5512media@precisionbiosciences.com
See original here:
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting - BioSpace
- genetic engineering summary | Britannica - September 13th, 2024
- The great gene editing debate: can it be safe and ethical? - BBC.com - September 13th, 2024
- Anti-biotechnology campaigners embrace classic crops, are suspicious of hybrid varieties and claim genetic modification violates nature. Heres a... - September 13th, 2024
- Will IL-11 Control Extend Human Life One Day? Early Results are Tantalizing - Securities.io - September 13th, 2024
- Viewpoint: As New Zealand edges toward relaxing its ban on gene edited foods, experts weigh in - Genetic Literacy Project - September 13th, 2024
- Farmers in Brazil and Argentina ramp up growing of genetically-modified drought tolerant wheat that can grow in subtropical regions - Genetic Literacy... - September 13th, 2024
- Scientist explains why we'll never have a real Jurassic Park - and people are crestfallen - indy100 - September 13th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021
- Gene editing, joke theft and manifesting - The Week UK - October 5th, 2021
- Opinion: Saving lives through real social justice - Agri-Pulse - October 5th, 2021
- Science, business and the humanities: CP Snow's 'Two Cultures' sixty years on - TheArticle - October 5th, 2021
- Probiotic Yeast Engineered To Produce Beta-Carotene - Technology Networks - April 17th, 2021
- In the US, Imminent Release of Genetically Modified Mosquitoes To Fight Dengue - The Wire Science - April 17th, 2021
- CRISPRoff: A New Addition to the CRISPR Toolbox - Technology Networks - April 17th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 17th, 2021
- Grammar of the Genome: Reading the Influence of DNA on Disease - Baylor University - April 17th, 2021
- We cannot let China set the standards for 21st century technologies | TheHill - The Hill - April 17th, 2021
- First GMO Mosquitoes to Be Released in the Florida Keys - Singularity Hub - April 17th, 2021
- Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations - BioSpace - April 17th, 2021
- AmunBio and NorthShore University to Advance Cancer Immunotherapy with Engineered Oncolytic Viruses - OncoZine - April 17th, 2021
- StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - BioSpace - April 17th, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 17th, 2021
- EU's refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal - Alliance for Science - Alliance for Science - February 14th, 2021
- New species of fly named after Singanallur Tank - The Hindu - February 14th, 2021
- Son of Monarchs Pays Homage to the Beauty of Migration - Sierra Magazine - February 14th, 2021
- Podcast: TIME's 2020 Kid of the Year, Gitanjali Rao - All Together - Society of Women Engineers - February 14th, 2021
- Geoengineering: What could possibly go wrong? Elizabeth Kolbert's take, in her new book - Bulletin of the Atomic Scientists - February 14th, 2021
- An Introduction to PCR - Technology Networks - February 14th, 2021
- Science Talk - Evolution, cancer and coronavirus how biology's 'Theory of Everything' is key to fighting cancer and global pandemics - The Institute... - February 14th, 2021
- 22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with... - February 14th, 2021
- Aleph Farms and The Technion Reveal World's First Cultivated Ribeye Steak - PRNewswire - February 9th, 2021
- Researchers create rice that captures more CO2 with 30 percent more yield - FoodIngredientsFirst - February 9th, 2021
- Interview: Elizabeth Kolbert on why well never stop messing with nature - Grist - February 9th, 2021
- Is Biotechnology the Answer to a More Sustainable Beauty Industry? - Fashionista - February 9th, 2021
- New Jersey arts and entertainment news, features, and event previews. - New Jersey Stage - February 9th, 2021
- CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft... - February 9th, 2021
- Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic... - February 9th, 2021
- A new tool to investigate bacteria behind hospital infections - MIT News - February 9th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 9th, 2021
- Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization - GlobeNewswire - February 9th, 2021
- Global Lab-On-A-Chip Market Industry Perspective, Comprehensive Analysis, and Forecast 2027||Players-Perkin Elmer Corporation, IDEX, Thermo Fisher... - February 9th, 2021
- Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium - PharmiWeb.com - February 9th, 2021
- Global Bacterial and Plasmid Vectors Market Report 2020: Market is Expected to Recover and Reach $0520 Million in 2023 at a CAGR of 15.48% - Forecast... - January 12th, 2021
- mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry - TIME - January 12th, 2021